Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Albumin-binding protein gp60, also known as albondin, is a 60 kDa cell surface glycoprotein primarily expressed on the luminal surface of vascular endothelial cells (Schnitzer et al., 1994, J. Biol. Chem. 269:6072-6082). It serves as a specific receptor for albumin, facilitating the transcytosis of albumin and albumin-bound molecules from the blood into the interstitial space (Tiruppathi et al., 1997, Proc. Natl. Acad. Sci. USA 94:1362-1367). This process is mediated through the activation of caveolae-mediated endocytosis upon albumin binding, involving interactions with caveolin-1 and Src-family kinases (Minshall et al., 2000, J. Cell Biol. 150:1057-1070). In the context of oncology, gp60 is exploited to enhance the delivery of albumin-bound chemotherapeutics, such as nab-paclitaxel (Abraxane), into tumor tissues (Desai et al., 2006, Clin. Cancer Res. 12:1317-1324). By leveraging the natural albumin transport pathway, these drugs can achieve higher intratumoral concentrations compared to conventional formulations. Beyond drug delivery, gp60 plays a critical role in maintaining vascular homeostasis and regulating fluid balance across the endothelium by controlling albumin flux. Dysregulation of gp60-mediated transport is associated with inflammatory conditions and increased vascular permeability (Vogel et al., 2001, Am. J. Physiol. Lung Cell Mol. Physiol. 281:L412-L422).
Binding of albumin to gp60 on the endothelial surface triggers the clustering of gp60 and its association with caveolin-1, initiating the formation of caveolae that transport albumin across the endothelial cell layer via transcytosis.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Albumin-binding protein gp60 (gp60) (gp60).